April 03, 2026 03:01 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
AAP drops Raghav Chadha from key parliamentary role, sparks buzz over internal rift | Amit Shah to camp in West Bengal for 15 days during Assembly polls; predicts Mamata’s defeat in state and Bhabanipur | 'BJP plotting President’s Rule, don’t fall in the trap': Mamata Banerjee on Malda unrest, urges peace | 'Most polarised state': CJI Kant raps Bengal govt over 9-hour hostage of judicial officers | Bengal SIR protest: Judge pleads for help amid mob attack after 9-hour hostage ordeal | Bengal SIR progress: 47 lakh of 60 lakh adjudicated cases disposed of, Supreme Court informed | Amit Shah to join Suvendu Adhikari on Bhabanipur nomination day; BJP plans mega roadshow | Fuel prices rise: Premium petrol, diesel hiked amid oil price surge | Commercial LPG up Rs 195.50 as global oil prices rise; domestic rates unchanged | Layoff alert: Oracle cuts 30,000 jobs globally, 12,000 hit in India
Bharat Biotech-Covaxin
Image tweeted by @IndianEmbassyTR

Regulatory approvals for Covaxin in process in more than 60 countries: Bharat Biotech says amid travel fears

| @indiablooms | May 26, 2021, at 05:44 am

Hyderabad/IBNS: Amid travel fears that students receiving Covaxin may not be allowed in many countries as the vaccine is not listed, Hyderabad-based pharma major Bharat Biotech on Tuesday said regulatory approvals for its indigenously developed Covid-19 vaccine are in process in more than 60 countries including the US, Brazil and Hungary.

The US, Canada, Australia, Ireland and the EU are among those who do not have Covaxin approved on their list of vaccines for now.

Meanwhile, top universities are reportedly allowing those who have received vaccines approved by the countries or World Health Organisation (WHO).

Emergency use authorisations (EUA) have been obtained from 13 countries with more to follow, Bharat Biotech informed.

It has submitted an application to the WHO to get a EUL (Emergency Use Listing) for indigenously developed Covid-19 vaccine Covaxin and regulatory approvals are expected by Jul-Sept 2021.

Most countries recommend vaccinations against COVID-19.

Unvaccinated travellers can travel with negative RT-PCR tests prior to travel, in the absence of any other country-specific travel restrictions.

Covaxin, which has been priced at around $15-20 per dose for the export market, has already received EUA in several countries like Mexico, Philippines, Iran, Paraguay, Guatemala, Nicaragua, Guyana, Venezuela, Botswana, Zimbabwe and Nepal.

On social media platform Twitter, Bharat Biotech Joint Managing Director Suchitra Ella said Covaxin reaches 30 cities within 30-day.

"All our employees are committed, working 24x7 thru lockdowns for the country’s immunization. Some of the employees are still quarantined and off work," she said.

The list of cities that Covaxin has reached through private hospital dispatches that include the metros and Tier-I cities like Bengalore, Delhi, Chennai, Hyderabad, Kolkata, Mumbai and Pune, Ella tweeted.

Dr. Raches Ella, Head-Business Development and International Advocacy of Bharath Biotech, while in a recent virtual conversation with members of FICCI Ladies Organisation (FLO) here, said we will soon ramp up its manufacturing capacity to 700 million doses by the end of this year.

The indigenous Covaxin vaccine is co-developed by Bharat Biotech and ICMR, Dr Raches said the Government placed an advanced purchase order of rupees 1500 crore and this will help our company to increase our risk appetite and that is why we are expanding to Bangalore and Gujarat.

With UNI inputs

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.